Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200-Day Moving Average – Time to Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.19 and traded as high as $5.38. Cumberland Pharmaceuticals shares last traded at $5.19, with a volume of 358,417 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Stock Performance

The firm has a market cap of $77.63 million, a PE ratio of -21.63 and a beta of -0.53. The stock has a 50-day moving average price of $2.93 and a 200 day moving average price of $3.19. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.23 and a quick ratio of 1.11.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. The business had revenue of $8.29 million for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 5.13% and a negative net margin of 8.06%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Heron Bay Capital Management purchased a new position in Cumberland Pharmaceuticals during the second quarter worth approximately $111,000. XTX Topco Ltd acquired a new stake in shares of Cumberland Pharmaceuticals during the 2nd quarter worth $34,000. Bridgeway Capital Management LLC increased its holdings in shares of Cumberland Pharmaceuticals by 2.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after buying an additional 4,200 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Cumberland Pharmaceuticals by 11.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after buying an additional 27,980 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,326 shares during the last quarter. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.